Minirin Spray (Desmopressin Acetate)

Desmopressin acetate, the active ingredient in Minirin Spray, is a vasopressin analog presented as a 10 µg per spray nasal spray for nasal use. It treats central diabetes insipidus and primary nocturnal enuresis by reducing urine output through antidiuretic hormone activity.

GNH USA supplies Minirin Spray as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory‑compliant shipments to global healthcare providers.

Desmopressin acetate is used to manage conditions related to antidiuretic hormone deficiency or nocturnal urinary leakage.

- Central diabetes insipidus: reduces excessive urine volume and thirst by concentrating urine. - Primary nocturnal enuresis: decreases nighttime bedwetting episodes by increasing water reabsorption.

Desmopressin nasal spray may cause a range of adverse reactions.

Common Side Effects: - Nasal irritation or congestion - Headache - Mild hyponatremia - Nausea - Thirst - Abdominal cramps

Serious or Rare Side Effects: - Severe hyponatremia leading to seizures or coma - Water intoxication with cerebral edema - Allergic reactions including rash or anaphylaxis - Nasal septum perforation (rare)

When prescribing or using Minirin Spray, several safety considerations apply.

- Serum sodium assessment: check baseline sodium levels before initiating therapy. - Fluid balance monitoring: advise patients to maintain a controlled fluid intake. - Lowest effective dose: start with the minimal dose that controls symptoms. - Hyponatremia risk: avoid use in patients with existing low sodium or uncontrolled heart failure. - Renal function: evaluate kidney function, especially in the elderly. - Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Desmopressin may interact with other medicines that affect water and electrolyte balance.

Major Interactions (Avoid): - Other antidiuretic hormone analogs: risk of profound hyponatremia. - Thiazide diuretics: additive water retention can precipitate severe hyponatremia.

Moderate Interactions (Monitor Closely): - Selective serotonin reuptake inhibitors (SSRIs) and SNRIs: may increase hyponatremia risk. - Carbamazepine: potential to lower serum sodium. - Non‑steroidal anti‑inflammatory drugs (NSAIDs): can reduce renal clearance of water. - Alcohol: may alter fluid balance and exacerbate hyponatremia.